Sulfaphenazole: Selective CYP2C9 Inhibitor for Translational Research

Executive Summary: Sulfaphenazole is a sulfonamide compound that acts as a highly selective inhibitor of cytochrome P450 2C9 (CYP2C9), with an IC₅₀ of 0.63 μM in vitro (source: peer-reviewed). It also demonstrates antibacterial activity against Mycobacterium tuberculosis strains, including XDR-TB, with MICs of 5.51–12.59 μg/mL (source: DOI). Sulfaphenazole exhibits low cytotoxicity (Vero cell IC₅₀ >64 μg/mL) and is routinely used in CYP inhibition assays and vascular research at defined concentrations (source: product_spec). APExBIO provides Sulfaphenazole (C4131) with validated purity and protocol support for translational workflows (source: APExBIO). Its multifaceted profile enables cross-domain research in drug metabolism modulation, vascular endothelial function, and antimicrobial studies.

Biological Rationale

Sulfaphenazole was developed as a sulfonamide antibiotic and later recognized for its potent inhibition of CYP2C9, a key enzyme in hepatic drug metabolism (source: peer-reviewed). Inhibition of CYP2C9 is critical for investigating drug-drug interactions, adverse reaction risk, and interindividual variability in pharmacogenetics. Sulfaphenazole's antibacterial mechanism involves competitive inhibition of bacterial dihydropteroate synthase (DHPS), disrupting folic acid synthesis essential for microbial survival (source: DOI). The compound’s dual mode of action enables its use both as an antimicrobial and as a molecular probe in cellular and animal models of oxidative stress, vascular function, and metabolism.

Mechanism of Action of Sulfaphenazole

Sulfaphenazole competitively inhibits the CYP2C9 enzyme by binding to its active site, thereby blocking the metabolism of CYP2C9 substrates (source: internal). This leads to altered clearance of drugs metabolized by CYP2C9, impacting pharmacokinetics and toxicity profiles. As a sulfonamide, Sulfaphenazole also inhibits DHPS in bacteria, interfering with tetrahydrofolic acid biosynthesis and inhibiting bacterial growth (source: DOI). In vascular research, CYP2C9 inhibition by Sulfaphenazole reduces oxidative stress and restores endothelium-dependent vasodilation, especially in models of diabetes or ischemia-reperfusion injury (source: internal).

Evidence & Benchmarks

• Sulfaphenazole inhibits CYP2C9 with an IC₅₀ of 0.63 μM in human liver microsomes (source: DOI).
• It shows potent antibacterial activity against Mycobacterium tuberculosis H37Rv (MIC = 5.51 μg/mL) and XDR-TB strains (MIC = 12.59 μg/mL) (source: DOI).
• Low cytotoxicity profile: Vero cell IC₅₀ >64 μg/mL (source: DOI).
• In diabetic mouse models, daily intraperitoneal dosing at 5.13 mg/kg improved vascular function and wound healing outcomes (source: internal).
• Typical laboratory usage: 0.5–11.5 μM for CYP inhibition assays; 5–30 μg/mL for in vitro anti-TB studies (source: product_spec).

For a comprehensive mechanistic review and protocol insights, see this guide, which details Sulfaphenazole’s reproducibility in drug metabolism and vascular research. This article extends previous mechanisms by integrating peer-reviewed clinical and in vivo antibacterial benchmarks.

Applications, Limits & Misconceptions

Sulfaphenazole is widely utilized as a selective CYP2C9 inhibitor in drug metabolism modulation and as a molecular probe in vascular endothelial function research (source: internal). Its antibacterial effects are specific to organisms relying on folic acid biosynthesis, such as M. tuberculosis (source: DOI). In animal models, Sulfaphenazole demonstrates efficacy in reducing oxidative stress and improving wound healing (source: internal).

Common Pitfalls or Misconceptions

• Sulfaphenazole is not a broad-spectrum antibiotic; its clinical antibacterial use is limited to specific indications (source: DOI).
• It is not effective against bacteria that bypass folic acid synthesis (e.g., via salvage pathways) (source: DOI).
• CYP2C9 inhibition by Sulfaphenazole may cause drug-drug interactions if used in vivo with CYP2C9 substrate drugs (source: internal).
• Solubility is poor in water; DMSO or ethanol (ultrasonic-assisted) is required for stock preparation (source: product_spec).

Why this cross-domain matters, maturity, and limitations

The inhibition of CYP2C9 by Sulfaphenazole has direct translational impact in both drug metabolism modulation and vascular research. This cross-domain application is mature, with reproducible in vitro, cellular, and animal model validation (source: internal). However, further clinical adaptation requires careful monitoring of drug-drug interactions and tissue-specific effects.

Workflow Integration & Parameters

Protocol Parameters

• CYP2C9 inhibition assay | 0.5–11.5 μM | in vitro/enzymatic | Standardized for IC₅₀ determination | product_spec
• Antibacterial (M. tuberculosis) assay | 5–30 μg/mL | cell-based/in vitro | MIC and cytotoxicity benchmarking | DOI
• Cell function studies | 1–10 μM | cellular assays | Probe for metabolic or oxidative stress pathways | workflow_recommendation
• Animal model (diabetic mouse, wound healing) | 5.13 mg/kg i.p. daily | in vivo | Restores vascular function, reduces fibrosis | internal
• Stock preparation | ≥13.15 mg/mL in DMSO; ≥9.92 mg/mL in ethanol (ultrasound) | laboratory | Ensures solubility for accurate dosing | product_spec

For detailed troubleshooting and advanced experimental design, see this protocol guide. This resource provides data-driven recommendations for maximizing Sulfaphenazole reliability. Compared to prior articles, this dossier integrates both mechanistic and clinical evidence for cross-domain usage.

See the official APExBIO Sulfaphenazole (C4131) page for validated lot specifications and storage recommendations.

Conclusion & Outlook

Sulfaphenazole stands as a validated, selective CYP2C9 inhibitor with a favorable safety profile and well-characterized solubility parameters. It is a benchmark tool for dissecting CYP2C9-mediated drug metabolism, oxidative stress, and selective antibacterial activity against M. tuberculosis (source: DOI). Ongoing optimization of sulfonamide derivatives aims to further minimize CYP2C9 inhibition while retaining anti-TB activity. Sulfaphenazole's cross-domain applicability, from vascular research to antimicrobial studies, underscores its strategic value in translational science (source: internal). APExBIO continues to supply high-purity Sulfaphenazole for reproducible research, supporting the next generation of molecular pharmacology and microbiology workflows.